BIOR Biora Therapeutics, Inc.

Biora Therapeutics Inc, formerly Progenity Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States. It generates revenue from providing molecular laboratory tests to customers.

$4.39  -0.38 (-7.97%)
As of 01/30/2023 15:59:53 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  06/19/2020
Outstanding shares:  223,170,617
Average volume:  24,153,389
Market cap:   $988,645,833
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -4.16
PB ratio:   -10.23
PS ratio:   832.89
Return on equity:   245.70%
Net income %:   -19,288.63%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy